Drug manufacturers are suing the FDA (Food and Drug Administration) because the agency announced that there is no longer a shortage of the weight-loss drug Wegovy. Some of these manufacturers produce medications like Ozempic, which is often used similarly to Wegovy.

**Summary for General Audience:**

Drugmakers are in a legal battle with the FDA over obesity and diabetes medications. Compounders, who create alternative versions of medications, are suing because the FDA removed semaglutide, a drug used in treatments like Wegovy and Ozempic, from its shortage list. This change means compounders can no longer offer their versions, which they argue will limit patient access to important treatments.

The lawsuit claims the FDA’s decision was unfair and made without proper notification or public input, despite ongoing supply issues. Online health company Hims & Hers, which sells compounded semaglutide, is advising customers to find other options due to the FDA’s ruling, which has impacted their stock value.

Hims plans to adapt by offering personalized doses of semaglutide to manage side effects and maintain drug adherence, expecting significant revenue from weight loss drugs despite changes.

Meanwhile, pharmaceutical companies Novo Nordisk and Eli Lilly are also challenging the FDA’s decision. Lilly is experimenting with a new sales strategy, including a self-pay program and reduced prices for its drug Zepbound, offering doses in vials at lower prices.